MEK3 Inhibitors
MEK3 inhibitors predominantly function through either direct inhibition of MEK3 or by disrupting the downstream targets in the MAPK pathway, specifically p38 MAPK. Inhibitors such as U0126 directly target MEK3 by binding to its inactive form and precluding its phosphorylation by upstream MKK kinases. This action results in a hindrance to p38 MAPK activation, a direct substrate of MEK3. Similarly, compounds like PD169316 and SB203580 selectively inhibit p38 MAPK and disrupt the feedback mechanism that stabilizes and activates MEK3. By p38 MAPK activation, these compounds cut off the downstream signaling essential for MEK3 stabilization.
Compounds such as SP600125 focus on the JNK-MEK3 interaction, thereby inhibiting the alternate pathway mediated by MEK3. In the same vein, dual inhibitors like BIRB 796 interfere with both the primary and alternative pathways by targeting p38 MAPK and JNK. Moreover, TAK-242 targets TLR4, an upstream modulator, thereby affecting MEK3's activation. The diversity in MEK3 inhibitors, either through direct targeting or indirect modulation via downstream or upstream effectors, allows for a range of options for precisely modulating MEK3 activity. Each compound uniquely influences the biochemical or cellular pathways in which MEK3 is involved, and this specificity is crucial for effective MEK3 inhibition.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, which is downstream of MEK3. By targeting p38 MAPK, it indirectly modulates MEK3 activity, as it disrupts the feedback loop essential for MEK3 stability. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
Selectively inhibits p38 MAPK activation, thereby indirectly affecting MEK3 by disrupting the downstream pathway in which MEK3 acts as a mediator for p38 MAPK phosphorylation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that impacts the JNK-MEK3 interaction, inhibiting downstream effects of MEK3 in the p38 MAPK pathway. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
Targets p38 MAPK, disrupting its activation and thus the feedback loop crucial for maintaining MEK3 protein stability and activation. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
Specifically targets p38 MAPK, blocking its activation. This, in turn, disrupts the downstream signaling that would typically stabilize MEK3 through a feedback mechanism. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Dual inhibitor for p38 MAPK and JNK, thereby interfering with both the primary and alternative pathways mediated by MEK3. | ||||||
Losmapimod | 585543-15-3 | sc-489299 sc-489299A | 10 mg 50 mg | $228.00 $825.00 | ||
p38 MAPK inhibitor that indirectly hampers MEK3 activity by breaking the feedback mechanism necessary for MEK3’s activation and stabilization. | ||||||
PD 184,352 | 212631-79-3 | sc-202759 sc-202759A | 1 mg 5 mg | $40.00 $260.00 | 34 | |
Targets MAPKAPK2, a downstream effector in the p38 MAPK pathway, thereby indirectly reducing the stabilizing feedback for MEK3. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
Targets TLR4, an upstream modulator of MEK3, to inhibit the activation of MEK3 and its downstream impact on p38 MAPK. | ||||||
PH-797804 | 586379-66-0 | sc-364579 sc-364579A sc-364579B | 5 mg 50 mg 500 mg | $92.00 $520.00 $2601.00 | ||
Inhibits p38 MAPK activation, disrupting the feedback loop essential for MEK3 activation and stabilization. | ||||||